Trikafta Exercise Study in Cystic Fibrosis
Recruiting now NCT05279040
Run by University of British Columbia · for 19 and older · All sexes
What this study is about
Shortness of breath (dyspnea) during exercise is a major source of distress and is a commonly reported symptom in patients with cystic fibrosis (CF). A recent drug treatment option known as Trikafta, which contains elexacaftor, tezacaftor, and ivacaftor, may be used in patients with CF to help improve lung health. However, the effects of this combination therapy on dyspnea and exercise performance, a known predictor of survival in CF, are not clear. The investigators aim to understand the effects of Trikafta on these symptoms and to gain new insight into the potential health improvements in CF from using this treatment option.
Who can join (things the study team will check)
✅ You may be able to join if…
- Confirmed diagnosis of CF and at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
- Plan to initiate Trikafta by the treating physician within 30 days of the enrolment visit
- Aged 19 years or older
- Stable clinical status based on clinical judgment of the treating physician
- Forced Expiratory Volume in 1 second (FEV1.0) < 90% predicted
- Body mass index greater than 16 or less than 30 kg/m\^2
- Currently non-smoking or a past smoking history of less than 20 pack-years
- Able to read and understand English
- Fully vaccinated (at least 2 doses) for Covid-19
🚫 You may not be able to join if…
- A disease other than CF that could importantly contribute to dyspnea or exercise limitation
- Chronic airway infection with Mycobacterium abscessus, Burkholderia cepacia complex, or other organisms with infection control implications based on the treating physicians
- Contraindications to clinical exercise testing
- Use of supplemental oxygen or desaturation less than 85% with exercise
- Diagnosis of pneumothorax in the past 4 weeks
- History of organ transplantation
Where this trial is running
- UBC Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, British Columbia, Canada
Who to contact
Satvir S Dhillon, MSc · 6048068835 · satvir.dhillon@hli.ubc.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT05279040.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.